

: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M : STAR.0000058762

UHID/MR No Visit ID

: STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected Received : 23/Sep/2023 10:05AM : 23/Sep/2023 10:59AM

Reported

: 23/Sep/2023 12:10PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Methodology: Microscopic
RBC: Normocytic normochromic
WBC: Normal in number, Eosinophilia
Platelets: Adequate in Number
Parasites: No Haemoparasites seen

IMPRESSION: Normocytic normochromic blood picture, Eosinophilia

Note/Comment: Please Correlate clinically

Page 1 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID Ref Doctor : STAROPV63405

Emp/Auth/TPA ID

: Dr.SELF

: 916366940449

Collected : 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 10:59AM

Reported

: 23/Sep/2023 12:10PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

45.30 5.61 80.8 26.1 32.3 12.8	% Million/cu.mm fL pg g/dL	40-50 4.5-5.5 83-101 27-32	PULSE HEIGHT AVERAGE Electrical Impedence Calculated Calculated
80.8 26.1 32.3	fL pg	83-101 27-32	Calculated
26.1 32.3	pg	27-32	
32.3			Calculated
	g/dL		
12.8		31.5-34.5	Calculated
	%	11.6-14	Calculated
8,530	cells/cu.mm	4000-10000	Electrical Impedance
DLC)			
48	%	40-80	Electrical Impedance
34	%	20-40	Electrical Impedance
11	%	1-6	Electrical Impedance
07	%	2-10	Electrical Impedance
00	%	<1-2	Electrical Impedance
4094.4	Cells/cu.mm	2000-7000	Electrical Impedance
2900.2	Cells/cu.mm	1000-3000	Electrical Impedance
938.3	Cells/cu.mm	20-500	Electrical Impedance
597.1	Cells/cu.mm	200-1000	Electrical Impedance
308000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOP
05	mm at the end of 1 hour	0-15	Modified Westergren
	48 34 11 07 00 4094.4 2900.2 938.3 597.1 308000	48 % 34 % 11 % 07 % 00 % 4094.4 Cells/cu.mm 2900.2 Cells/cu.mm 938.3 Cells/cu.mm 597.1 Cells/cu.mm 308000 cells/cu.mm 05 mm at the end	48 % 40-80 34 % 20-40 11 % 1-6 07 % 2-10 00 % <1-2

Methodology: Microscopic
RBC: Normocytic normochromic
WBC: Normal in number, Eosinophilia
Platelets: Adequate in Number
Parasites: No Haemoparasites seen

IMPRESSION: Normocytic normochromic blood picture, Eosinophilia

Note/Comment: Please Correlate clinically

Page 2 of 16



SIN No:BED230231389

Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)
CIN- U85100TG2009PTC099414

Regd Off:1-10-62/62 ,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016



: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No Visit ID : STAR.0000058762 : STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 10:59AM

Reported

: 23/Sep/2023 12:00PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

BLOOD GROUP ABO AND RH FAC	,=============================	
BLOOD GROUP TYPE	0	Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE	Forward & Reverse Grouping with Slide/Tube Agglutination

Page 3 of 16



Regd Off:1-10-62/62 ,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016



: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID Ref Doctor : STAROPV63405

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:01AM

Reported

: 23/Sep/2023 12:40PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

GLUCOSE, FASTING , NAF PLASMA	93	mg/dL	70-100	GOD - POD	
-------------------------------	----	-------	--------	-----------	--

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 4 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID Ref Doctor : STAROPV63405

Emp/Auth/TPA ID

: 916366940449

: Dr.SELF

Collected

: 23/Sep/2023 01:59PM

Received

: 23/Sep/2023 02:17PM

Reported

: 23/Sep/2023 02:27PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2	93	mg/dL	70-140	GOD - POD
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID Ref Doctor : STAROPV63405

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 03:15PM

Reported

: 23/Sep/2023 04:55PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.7	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD EDTA	117	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF > 25%

B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 16



: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID Ref Doctor : STAROPV63405 : Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 03:15PM

Reported

: 23/Sep/2023 04:55PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Range Method

Page 7 of 16



SIN No:EDT230087582

Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

Regd Off:1-10-62/62 ,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016



: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID Ref Doctor : STAROPV63405

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported

: 23/Sep/2023 12:10PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 **Test Name** Result Unit Bio. Ref. Range Method

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	145	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	140	mg/dL	<150	
HDL CHOLESTEROL	27	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	118	mg/dL	<130	Calculated
LDL CHOLESTEROL	90	mg/dL	<100	Calculated
VLDL CHOLESTEROL	28	mg/dL	<30	Calculated
CHOL / HDL RATIO	5.37		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350 mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 8 of 16



: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M : STAR.0000058762

UHID/MR No Visit ID

: STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received Reported : 23/Sep/2023 11:04AM : 23/Sep/2023 12:10PM

Status

20/00p/2020 12.1

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name

Result

Unit

Bio. Ref. Range

Method

Page 9 of 16



SIN No:SE04490528

Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

Regd Off:1-10-62/62 ,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016



Patient Name : Mr.YOGESH S MESHRAM

Age/Gender : 36 Y 0 M 28 D/M UHID/MR No : STAR.0000058762

Visit ID : STAROPV63405

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 916366940449

Collected : 23/Sep/2023 10:05AM

Received : 23/Sep/2023 11:04AM Reported : 23/Sep/2023 12:35PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.70	mg/dL	0.1-1.2	Azobilirubin
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	0.1-0.4	DIAZO DYE
BILIRUBIN (INDIRECT)	0.50	mg/dL		
ALANINE AMINOTRANSFERASE (ALT/SGPT)	24	U/L	4-44	JSCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	22.0	U/L	8-38	JSCC
ALKALINE PHOSPHATASE	95.00	U/L	32-111	IFCC
PROTEIN, TOTAL	7.50	g/dL	6.7-8.3	BIURET
ALBUMIN	4.80	g/dL	3.8-5.0	BROMOCRESOL GREEN
GLOBULIN	2.70	g/dL		Calculated
A/G RATIO	1.78			Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen

to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment:

Page 10 of 16



: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID Ref Doctor

: STAROPV63405

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported

: 23/Sep/2023 12:35PM

Status Sponsor Name : Final Report

ne

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 11 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M : STAR.0000058762

UHID/MR No Visit ID

: STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported

: 23/Sep/2023 12:00PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 **Test Name** Result Unit Bio. Ref. Range Method

CREATININE	0.73	mg/dL	0.6-1.1	ENZYMATIC METHOD
UREA	20.50	mg/dL	17-48	Urease
BLOOD UREA NITROGEN	9.6	mg/dL	8.0 - 23.0	Calculated
URIC ACID	6.30	mg/dL	4.0-7.0	URICASE
CALCIUM	9.50	mg/dL	8.4-10.2	CPC
PHOSPHORUS, INORGANIC	3.00	mg/dL	2.6-4.4	PNP-XOD
SODIUM	141	mmol/L	135-145	Direct ISE
POTASSIUM	4.5	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	104	mmol/L	98-107	Direct ISE

Page 12 of 16



Regd Off: 1-10-62/62, 5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016



: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M : STAR.0000058762

UHID/MR No Visit ID

: STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

(GGT), SERUM

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported

: 23/Sep/2023 12:00PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

method

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method GAMMA GLUTAMYL TRANSPEPTIDASE 52.00 U/L 16-73 Glycylglycine Kinetic

Page 13 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No Visit ID

: STAR.0000058762

Ref Doctor

: STAROPV63405

Emp/Auth/TPA ID

: Dr.SELF : 916366940449

Collected Received

: 23/Sep/2023 10:05AM

: 23/Sep/2023 11:04AM

Reported

: 23/Sep/2023 01:47PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 **Test Name** Result Unit Bio. Ref. Range Method

THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	0.97	ng/mL	0.67-1.81	ELFA		
THYROXINE (T4, TOTAL)	6.23	μg/dL	4.66-9.32	ELFA		
THYROID STIMULATING HORMONE (TSH)	1.590	μIU/mL	0.25-5.0	ELFA		

Comment:

Note:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 14 of 16

Begumpet, Hyderabad, Telangana - 500016

Address:



: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M : STAR.0000058762

UHID/MR No Visit ID

: STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 916366940449

Test Name

Collected

: 23/Sep/2023 10:05AM : 23/Sep/2023 11:04AM

Received Reported

: 23/Sep/2023 01:47PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Result Unit Bio. Ref. Range Method

High High High High Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 15 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M : STAR.0000058762

UHID/MR No Visit ID

: STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:19AM

Reported

: 23/Sep/2023 12:10PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (C	UE) , <i>URINE</i>			
PHYSICAL EXAMINATION			4	
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.015		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MO	OUNT AND MICROSCOPY			
PUS CELLS	0-1	/hpf	0-5	Microscopy
EPITHELIAL CELLS	0-1	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

*** End Of Report ***

DR. APEKSHA MADAN MBBS, DPB PATHOLOGY Dr.Sandip Kumar Banerjee M.B.B.S,M.D(PATHOLOGY),D.P.B Consultant Pathologist

Page 16 of 16



SIN No:UR2189629

Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited) CIN- U85100TG2009PTC099414

Regd Off:1-10-62/62 ,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016



प्रति

समन्वयक,

Mediwheel (Arcofemi Healthcare Limited)

हेल्पलाइन नंबर: 011-41195959

महोदय/ महोदया,

विषय: बैंक ऑफ़ बड़ौदा के कर्मचारियों के लिए वार्षिक स्वास्थ्य जांच।

हम आपको सूचित करना चाहते हैं कि हमारे कर्मचारी की पत्नी/पति जिनके विवरण निम्नानुसार हैं हमारे करार के अनुसार आपके द्वारा उपलब्ध कराई गई कैशलेस वार्षिक स्वास्थ्य जांच सुविधा का लाभ लेना चाहते हैं।

	स्वास्थ्य जांच लाभार्थी केविवरण
नाम	YOGESH SURESHMESHRAM
जन्म की तारीख	26-08-1987
कर्मचारी की पत्नी/पति के स्वास्थ्य जांच की प्रस्तावित तारीख	23-09-2023
बुकिंग संदर्भ सं.	23S163924100068592S
BAANA-1117	पत्नी/पति केविवरण
कर्मचारी का नाम	MS. SOMKUWAR RAJINI TIKARAMJI
कर्मचारी की क.कूसंख्या	163924
कर्मचारी का पद	BRANCH OPERATIONS
कर्मचारी के कार्य का स्थान	MUMBAI,PRABHADEVI
कर्मचारी के जन्म की तारीख	26-07-1988

यह अनुमोदन/ संस्तुति पत्र तभी वैध माना जाएगा जब इसे बैंक ऑफ़ बड़ौदा के कर्मचारी आईडी कार्ड की प्रति के साथ प्रस्तुत किया जाएगा। यह अनुमोदन पत्र दिनांक 05-09-2023 से 31-03-2024 तक मान्य है। इस पत्र के साथ किए जाने वाले चिकित्सा जांच की सूची अनुलग्नक के रूप में दी गई है। कृपया नोट करें कि उक्त स्वास्थ्य जांच हमारी टाई-अप व्यवस्था के अनुसार कैशलेस सुविधा है। हम अनुरोध करते हैं कि आप हमारे कर्मचारी के पत्नी/पित की स्वास्थ्य जांच संबंधी आवश्यकताओं पर उचित कार्रवाई करें तथा इस संबंध में अपनी सर्वोच्च प्राथमिकता तथा सर्वोत्तम संसाधन उपलब्ध कराएं। उपर्युक्त सारणी में दी गई कर्मचारी कूट संख्या एवं बुकिंग संदर्भ संख्या का उल्लेख अनिवार्य रूप से इनवॉइस में किया जाना चाहिए।

हम इस संबंध में आपके सहयोग की अपेक्षा करते हैं।

भवदीय.

हस्ता/-

(मुख्य महाप्रबंधक)

मानव संसाधन प्रबंधन विभाग

बैंक ऑफ़ बडौदा

(नोट: यह कंप्यूटर द्वारा जनरेट किया गया पत्र है। हस्ताक्षर की आवश्यकता नहीं है। कृपया किसी भी स्पष्टीकरण के लिए Mediwheel (Arcofemi Healthcare Limited)से संपर्क करें।)







OUT- PATIENT RECORD

Date

2319123

MRNO Name

Age/Gender

58762 MR. Jogesh Meshram

Mobile No Passport No Aadhar number

Pulse: 50	BP: 120180	Resp: 22	Temp: (N)
Weight: 86.8 Kg.	Height: 141 (·m·	BMI: 29.7	Waist Circum: 92 cm

General Examination / Allergies History


Clinical Diagnosis & Management Plan

Married, Norregetanian Sleep: @ BB@ No Alleryy. No addiction

Moderately Active PH: father: Flor morter: DM.

HDL27.

- morning walk 45 minderly



Signature

Follow up date:

Apollo Spectra Hospitals

156, Famous Cine Labs, Behind Everest Building, Tardeo, Mumbai, Maharashtra 400034



Patient Name: Yogesh M. Age: 36

Address: Chambur Date: 239 203



Signature

Dr. Rinal Modi B.D.S (Mumbai)

Dental Surgeon

Reg. No. : A -28591

M: 87792 56365 / 98922 90876

E:doctorrinal@gmail.com





: Mr.YOGESH S MESHRAM

Age/Gender UHID/MR No

Visit ID

: 36 Y 0 M 28 D/M

: STAR.0000058762

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 916366940449

: STAROPV63405

Collected Received : 23/Sep/2023 10:05AM

: 23/Sep/2023 10:59AM : 23/Sep/2023 12:10PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Methodology: Microscopic RBC: Normocytic normochromic WBC : Normal in number, Eosinophilia Platelets : Adequate in Number Parasites: No Haemoparasites seen

IMPRESSION: Normocytic normochromic blood picture, Eosinophilia

Note/Comment : Please Correlate clinically

Page 1 of 16



SIN No:BED230231389





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

Visit ID

: STAR.0000058762 : STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 10:59AM

Reported Status : 23/Sep/2023 12:10PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	HAEMATOLOG	Y	
ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUA	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

HAEMOGLOBIN	14.6	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	45.30	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.61	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	80.8	fL	83-101	Calculated
MCH	26.1	pg	27-32	Calculated
MCHC	32.3	g/dL	31.5-34.5	Calculated
R.D.W	12.8	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,530	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			
NEUTROPHILS	48	%	40-80	Electrical Impedance
LYMPHOCYTES	34	%	20-40	Electrical Impedance
EOSINOPHILS	11	%	1-6	Electrical Impedance
MONOCYTES	07	%	2-10	Electrical Impedance
BASOPHILS	00	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	4094.4	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	2900.2	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	938.3	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	597.1	Cells/cu.mm	200-1000	Electrical Impedance
PLATELET COUNT	308000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOP
ERYTHROCYTE SEDIMENTATION RATE (ESR)	05	mm at the end of 1 hour	0-15	Modified Westergren

Methodology: Microscopic
RBC: Normocytic normochromic
WBC: Normal in number, Eosinophilia
Platelets: Adequate in Number
Parasites: No Haemoparasites seen

IMPRESSION: Normocytic normochromic blood picture, Eosinophilia

Note/Comment: Please Correlate clinically

Page 2 of 16



SIN No:BED230231389





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No Visit ID

: STAR.0000058762

Ref Doctor

: STAROPV63405

: Dr.SELF Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 10:59AM

Reported Status

: 23/Sep/2023 12:00PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	HAEMATOLO	GY	
ARCOFEMI - MEDIWHEE	- FULL BODY ANNUA	L PLUS MALE	- 2D ECHO - PAN INDIA -	FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP TYPE	0	Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE	Forward & Reverse Grouping with Slide/Tube Agglutination

Page 3 of 16







: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

Visit ID

: STAR.0000058762 : STAROPV63405

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 916366940449 Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:01AM

Reported

: 23/Sep/2023 12:40PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	BIOCHEMIST	RY	
ARCOFEMI - MEDIWHEE	L - FULL BODY ANNUA	L PLUS MALE	- 2D ECHO - PAN INDIA - I	FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GLUCOSE, FASTING , NAF PLASMA	93	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 4 of 16



SIN No:PLF02031761





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No Visit ID

: STAR.0000058762

Ref Doctor

: STAROPV63405 : Dr.SELF

Emp/Auth/TPA ID : 916366940449 Collected

: 23/Sep/2023 01:59PM

Received

: 23/Sep/2023 02:17PM

Reported Status

: 23/Sep/2023 02:27PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

······································				
	DEPARTMENT OF	F BIOCHEMISTR	Y	
ARCOFEMI - MEDIWHEE	- FULL BODY ANNUA	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio, Ref. Range	Method

GLUCOSE, POST PRANDIAL (PP), 2	93	mg/dL	70-140	GOD - POD
HOURS, SODIUM FLUORIDE PLASMA (2		-		
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 16



SIN No:PLP1371945





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

Visit ID

: STAR.0000058762

Ref Doctor

: STAROPV63405

Emp/Auth/TPA ID

: 916366940449

: Dr.SELF

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 03:15PM

Reported

: 23/Sep/2023 04:55PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	BIOCHEMISTR	Υ	
ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUA	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.7	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD EDTA	117	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	****
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No : STAR.0000058762 Visit ID

Ref Doctor

: STAROPV63405

: Dr.SELF Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 03:15PM

Reported Status

: 23/Sep/2023 04:55PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	BIOCHEMIST	RY	
ARCOFEMI - MEDIWHEE	L - FULL BODY ANNUA	L PLUS MALE	- 2D ECHO - PAN INDIA -	FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

Page 7 of 16



SIN No:EDT230087582





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No Visit ID

: STAR.0000058762 : STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported Status

: 23/Sep/2023 12:10PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

		· · · · · · · · · · · · · · · · · · ·		
	DEPARTMENT OF	F BIOCHEMISTF	RY	
ARCOFEMI - MEDIWHEEL -	FULL BODY ANNUA	L PLUS MALE	- 2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

LIPID PROFILE , SERUM				ya — ananya ya mananya
TOTAL CHOLESTEROL	145	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	140	mg/dL	<150	
HDL CHOLESTEROL	27	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	118	mg/dL	<130	Calculated
LDL CHOLESTEROL	90	mg/dL	<100	Calculated
VLDL CHOLESTEROL	28	mg/dL	<30	Calculated
CHOL / HDL RATIO	5.37	~ >.	0-4.97	Calculated .

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350 mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 8 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

Visit ID

: STAR.0000058762

Ref Doctor

: STAROPV63405 : Dr.SELF

Emp/Auth/TPA ID : 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported Status : 23/Sep/2023 12:10PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	BIOCHEMIST	RY	
ARCOFEMI - MEDIWHEE	L - FULL BODY ANNUA	L PLUS MALE	- 2D ECHO - PAN INDIA - I	FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

Page 9 of 16







: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

Visit ID

: STAR.0000058762

Ref Doctor

: STAROPV63405 : Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported Status

: 23/Sep/2023 12:35PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method						

LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.70	mg/dL	0.1-1.2	Azobilirubin
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	0.1-0.4	DIAZO DYE
BILIRUBIN (INDIRECT)	0.50	mg/dL		
ALANINE AMINOTRANSFERASE (ALT/SGPT)	24	U/L	4-44	JSCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	22.0	U/L	8-38	JSCC
ALKALINE PHOSPHATASE	95.00	U/L	32-111	IFCC
PROTEIN, TOTAL	7.50	g/dL	6.7-8.3	BIURET
ALBUMIN	4.80	g/dL	3.8-5.0	BROMOCRESOL GREEN
GLOBULIN	2.70	g/dL		Calculated
A/G RATIO	1.78			Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > IIn Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen

to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment:

Page 10 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

Visit ID

: STAR.0000058762

Ref Doctor

: STAROPV63405

: Dr.SELF Emp/Auth/TPA ID : 916366940449 Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported Status

: 23/Sep/2023 12:35PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method						

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 11 of 16







: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID Ref Doctor : STAROPV63405

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported Status

: 23/Sep/2023 12:00PM

: Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY							
ARCOFEMI - MEDIWHEEL - F	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method							

CREATININE	0.73	mg/dL	0.6-1.1	ENZYMATIC METHOD
UREA	20.50	mg/dL	17-48	Urease
BLOOD UREA NITROGEN	9.6	mg/dL	8.0 - 23.0	Calculated
URIC ACID	6.30	mg/dL	4.0-7.0	URICASE
CALCIUM	9.50	mg/dL	8.4-10.2	CPC
PHOSPHORUS, INORGANIC	3.00	mg/dL	2.6-4.4	PNP-XOD
SODIUM	141	mmol/L	135-145	Direct ISE
POTASSIUM	4.5	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	104	mmol/L	98-107	Direct ISE

Page 12 of 16







: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

Visit ID

: STAR.0000058762 : STAROPV63405

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM : 23/Sep/2023 12:00PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method						

GAMMA GLUTAMYL TRANSPEPTIDASE	52.00	Ų/L	16-73	Glycylglycine Kinetic
(GGT), SERUM				method

Page 13 of 16







: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID

: STAROPV63405

Ref Doctor Emp/Auth/TPA ID

: 916366940449

: Dr.SELF

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported

: 23/Sep/2023 01:47PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method						

THYROID PROFILE TOTAL (T3, T4, TSH),	SERUM				***************************************
TRI-IODOTHYRONINE (T3, TOTAL)	0.97	ng/mL	0.67-1.81	ELFA	
THYROXINE (T4, TOTAL)	6.23	μg/dL	4.66-9.32	ELFA	
THYROID STIMULATING HORMONE (TSH)	1.590	μIU/mL	0.25-5.0	ELFA	

Comment:

Note:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	Ν	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	Ν	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 14 of 16





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID

: STAROPV63405

Ref Doctor Emp/Auth/TPA ID

: 916366940449

: Dr.SELF

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:04AM

Reported Status

: 23/Sep/2023 01:47PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY							
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324							
Test Name Result Unit Bio. Ref. Range Method							

High Pituitary Adenoma; TSHoma/Thyrotropinoma High High High

Page 15 of 16



SIN No:SPL23135846





: Mr.YOGESH S MESHRAM

Age/Gender

: 36 Y 0 M 28 D/M

UHID/MR No

: STAR.0000058762

Visit ID Ref Doctor : STAROPV63405

: Dr.SELF

Emp/Auth/TPA ID

: 916366940449

Collected

: 23/Sep/2023 10:05AM

Received

: 23/Sep/2023 11:19AM

Reported Status

: 23/Sep/2023 12:10PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DE	EPARTMENT OF CL	INICAL PATHOL	.OGY	
ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUA	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

COMPLETE URINE EXAMINATION (CU	JE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.015		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MO	UNT AND MICROSCOPY			
PUS CELLS	0-1	/hpf	0-5	Microscopy
EPITHELIAL CELLS	0-1	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

*** End Of Report ***

DR. AREKSHA MADAN

MBBS, DPB **PATHOLOGY** Dr. Sandip Kumar Banerjee M.B.B.S,M.D(PATHOLOGY),D.P.B

Consultant Pathologist

Page 16 of 16



SIN No:UR2189629

EYE REPORT



N	2	m	0	ŧ	

Yogah Meshoran

Date: 23 69/2000

Age /Sex:

337 /M

Ref No.:

Complaint:

100 ocular clo No alo SETAN

Examination

V4 6/A-

Near Catro

Spectacle Rx

		Righ	t Eye					
	Vision	Sphere	Cyl.	Axis	Vision	Sphere	Cyl.	Axis
Distance								
Read								a production of the second of

	0	m	2	rk	620	0
B #	8	# E I	O	8 8.0	2	В

Mon G. J. Wine

Medications:

Trade Name	Frequency	Duration

Follow up:

freeden & vin

Consultant:

Apollo Spectra Hospitals Famous Cine Labs, 156, Pt. M. M. Malviya Road, Tardeo, Mumbai - 400 034. Tel.: 022 4332 4500 www.apollospectra.com





logesh Mesham

Height

171cm

23. 9. 2023 Date

Time

APOLLO SPECTRA HOSPITAL

Segmental Lean

Trunk 28. 5kg Normal

3. 6kg

Normal

8.5 kgNormal Lean Mass

Evaluation

 $3.7 \, \text{kg}$

Normal

8.4kg

Normal

Age

Gender

Male

10:29:03

Body	Com	position
~~~,	~~	P

	Vary care								Ô۷ε	ľ		UNIT%	Normal Range
Weight	40	55	70	85 M861	160	115	130	86. 8	160 kg	175	190	205	54. 7 ~ 74. 0
Muscle Mass Skeletal Muscle Mass	60	70	80	90	100	1i0 ■ 33	120 . () kg	130	140	150	160	170	27. 4 <b>~</b> 33. 5
Body Fat Mass	20	40	60	80	100	160	220	280	28.7	400 kg	460	520	7. 7 ~ 15. 4
T B W Total Body Water	42. 7	7 kg (3	36. 2	~ 44.	2)		F F Fat Fre				58	3. 1 kg	(47. 0~ 58. 5)
Protein	11. 5	5 kg (S	9. 7~	11.8	3)		Mir	nera	*		3.	90 kg	(3. 35~4. 09)

* Mineral is estimated.

### **Obesity Diagnosis**

Obesity Diagnosis	S		Nutritional Evaluation	n	
	eritarini ter	Normal Range	Protein ☑Normal	□ Deficient	
BMI (100 (mm²)			Mineral ☑Normal	□ Deficient	
Body Mass Index (kg/m²)	29. 7	18. $5 \sim 25.0$	Fat □Normal	□ Deficient	<b>☑</b> Excessive
			Weight Managemen	t	
PBF (%)	33. 0	10.0 ~ 20.0	Weight   Normal	□Under	<b>☑</b> Over
Percent Body Fat	337 0	2010 2010	SMM ☑ Normal	□ Under	☐ Strong
\A/	***************************************		Fat □Normal	□ Under	✓ Over
WHR Waist-Hip Ratio	1. 10	0.80~0.90	Obesity Diagnosis		
D 64 D			B M   Normal	□ Under □ Extremely	<b></b> Over Over
BMR (kcal)	1625	1804 ~ 2123	PBF Norma	□ Under	☑ Over
			WHR □ Normal	☐ Under	☑ Over

Segmental Fa	PBF Fat Mass Evaluation
34. 5%	33, 5%
2. 0kg	2.0 kg
	Over unk . 4%
*******	5kg over
27. 4%	27. 6%
3. 4kg	3. 4 kg
Over	Over

#### Muscle-Fat Control

**Muscle Control** 

 $0.0 \, kg$ 

**Fat Control** 

18.4 k

**Eitness Score** 

65

# Impedance

Z	RA	LA	TR	RL	LL
20kHz	293. 1	<b>LA</b> [ 3 <b>0</b> 3. 0	25.6	310.5	299.0
100047	257 9	266.7	20.9	271.6	261.8

Use your results as reference when consulting with your physician or fitness trainer.

#### Exercise Planner Plan your weekly exercises from the follow mate your weight loss from those activities.

Energy	expendi	ture of	each activ	/ity(base	weight:	86. 8 kg	/ Durati	on:30m	in./unit:	kcal)	
ħ	Walking	120	Jogging		Bicycle		Swim	L	Mountain Climbing	/ند	Aerobic
Ä	174	P	304		260	4	304	7	283		304
Di.	Table tennis	<b>.</b>	Tennis	· <b>-</b> *⁄	Football	:	Oriental Fencing	4.	Gate ball	<b>14</b>	Badminton
Λ	196	不	260	<b>7.</b>	304	人	434	$V^{\mathcal{F}}$	165		196
2.	Racket ball	21/	Tae- kwon-do		Squash	**	7 Basketball	(2)	Rope jumping	~	Golf
Λ	434		434	77	434	久	260	N	304		153
	Push-ups	<u>&amp;</u>	Sit-ups	ଜ	Weight training	ů.	Dumbbell exercise		Elastic band	. i	Squats
	development of upper body		abdominal muscle training	مساله.	backache prevention	K	muscle strength		muscle strength	7	maintenance of lower body muscle

### • How to do

- 1. Choose practicable and preferable activities from the left.
- 2. Choose exercises that you are going to do for 7 days.
- 3. Calculate the total energy expenditure for a week.
- 4. Estimate expected total weight loss for a month using the formula shown below.
- Recommended calorie intake per day

1700

*Calculation for expected total weight loss for 4 weeks: Total energy expenditure (kcal/week) X 4weeks ÷ 7700



: Mr. YOGESH S MESHRAM

Age

: 36 Y M

UHID

: STAR.0000058762

OP Visit No

: STAROPV63405

Reported on

: 23-09-2023 12:11

Printed on

: 23-09-2023 12:11

Adm/Consult Doctor

Ref Doctor

: SELF

#### DEPARTMENT OF RADIOLOGY

#### X-RAY CHEST PA

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen.

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

### **CONCLUSION:**

No obvious abnormality seen.

Printed on:23-09-2023 12:11

---End of the Report---

Dr. VINOD SHETTY

Radiology



Name

: Mr. Yogesh Meshram

Age

: 36 Year(s)

Date

: 23/09/2023

Sex

: Male

Visit Type : OPD

## **ECHO Cardiography**

### **Comments:**

Normal cardiac dimensions.

Structurally normal valves.

No evidence of LVH.

Intact IAS/IVS.

No evidence of regional wall motion abnormality.

Normal LV systolic function (LVEF 60%).

No diastolic dysfunction.

Normal RV systolic function.

No intracardiac clots / vegetation/ pericardial effusion.

No evidence of pulmonary hypertension.PASP=30mmHg.

IVC 12 mm collapsing with respiration.

### **Final Impression:**

NORMAL 2DECHOCARDIOGRAPHY REPORT.

DR.CHHAYA P.VAJA. M. D.(MUM) NONINVASIVE CARDIOLOGIST



Name

: Mr. Yogesh Meshram

Age

: 36 Year(s)

Date : 23/09/2023

Sex

: Male

Visit Type : OPD

**Dimension:** 

EF Slope

60mm/sec

**EPSS** 

06mm

LA

34mm

ΑO

34mm

LVID (d)

49mm

LVID(s)

20mm

IVS (d)

11mm

LVPW (d)

11mm

**LVEF** 

60% (visual)

DR.CHHAYA . VAJA. M. D.(MUM) NONINVASIVE CARDIOLOGIST



Patient Name: MR. YOGESH MESHRAM

Ref. By

: HEALTH CHECK UP

Date: 23-09-2023 Age: 36 years

SONOGRAPHY OF ABDOMEN AND PELVIS

The liver is normal in size but shows mild diffuse increased echotexture suggestive LIVER:

of fatty infiltration (Grade I). No focal mass lesion is seen. The intrahepatic biliary tree

& venous radicles appear normal. The portal vein and CBD appear normal.

GALL

:The gall bladder is well distended and reveals normal wall thickness. There is no

**BLADDER** evidence of calculus seen in it.

PANCREAS: The pancreas is normal in size and echotexture. No focal mass lesion is seen.

:The spleen is normal in size and echotexture. No focal parenchymal mass lesion SPLEEN

is seen. The splenic vein is normal.

**<u>KIDNEYS</u>**: The **RIGHT KIDNEY** measures 11.0 x 3.4 cms and the **LEFT KIDNEY** measures

11.1 x 4.9 cms in size. Both kidneys are normal in size, shape and echotexture. There

is no evidence of hydroneprosis or calculi seen on either side.

The para-aortic & iliac fossa regions appears normal. There is no free fluid or any

lymphadenopathy seen in the abdomen.

**PROSTATE**: The prostate measures 3.1 x 2.3 x 2.2 cms and weighs 8.5 gms. It is normal in size,

shape and echotexture. No prostatic calcification is seen.

**URINARY**: The urinary bladder is well distended and is normal in shape and contour.

No intrinsic lesion or calculus is seen in it. The bladder wall is normal in thickness. **BLADDER** 

The Ultrasound examination reveals mild fatty infiltration of the Liver. IMPRESSION:


No other significant abnormality is detected.

Report with compliments.

DR.VINOD V.SHETTY

MD, D.M.R.D.

CONSULTANT SONOLOGIST.





Patient Name : Mr. YOGESH S MESHRAM Age/Gender : 36 Y/M

 UHID/MR No.
 : STAR.0000058762
 OP Visit No
 : STAROPV63405

 Sample Collected on
 : 23-09-2023 12:11

**Ref Doctor** : SELF

**Emp/Auth/TPA ID** : 916366940449

#### DEPARTMENT OF RADIOLOGY

#### X-RAY CHEST PA

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen .

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

# **CONCLUSION:**

No obvious abnormality seen.

**Dr. VINOD SHETTY**Radiology



Patient Name : Mr. YOGESH S MESHRAM Age/Gender : 36 Y/M

 UHID/MR No.
 : STAR.0000058762
 OP Visit No
 : STAROPV63405

 Sample Collected on
 : 23-09-2023 11:42

Ref Doctor : SELF

**Emp/Auth/TPA ID** : 916366940449

#### DEPARTMENT OF RADIOLOGY

#### **ULTRASOUND - WHOLE ABDOMEN**

LIVER: The liver is normal in size but shows mild diffuse increased echotexture suggestive

of fatty infiltration (Grade I). No focal mass lesion is seen. The intrahepatic biliary tree

& venous radicles appear normal. The portal vein and CBD appear normal.

GALL :The gall bladder is well distended and reveals normal wall thickness. There is no

**BLADDER** evidence of calculus seen in it.

**PANCREAS**: The pancreas is normal in size and echotexture. No focal mass lesion is seen.

**SPLEEN** :The spleen is normal in size and echotexture. No focal parenchymal mass lesion

is seen. The splenic vein is normal.

**KIDNEYS**: The **RIGHT KIDNEY** measures 11.0 x 3.4 cms and the **LEFT KIDNEY** measures

11.1 x 4.9 cms in size. Both kidneys are normal in size, shape and echotexture. There

is no evidence of hydroneprosis or calculi seen on either side.

The para-aortic & iliac fossa regions appears normal. There is no free fluid or any

lymphadenopathy seen in the abdomen.

**PROSTATE:** The prostate measures 3.1 x 2.3 x 2.2 cms and weighs 8.5 gms. It is normal in size,

shape and echotexture. No prostatic calcification is seen.

URINARY : The urinary bladder is well distended and is normal in shape and contour.

**BLADDER** No intrinsic lesion or calculus is seen in it. The bladder wall is normal in thickness.

IMPRESSION: The Ultrasound examination reveals mild fatty infiltration of the Liver.

No other significant abnormality is detected.

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.

**Dr. VINOD SHETTY**Radiology